+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating maridebart cafraglutide as an additional treatment to standard care to reduce heart failure events, cardiovascular deaths, and improve symptoms in adults with heart failure who have preserved or mildly reduced ejection fraction and obesity. This phase 3 global trial includes a double-blind period followed by an open-label extension. The study will continue until approximately 850 primary endpoint events have occurred, focusing on serious heart failure outcomes. Participants will be randomly assigned to receive either maridebart cafraglutide or a placebo, both given by subcutaneous injection. The trial includes two parts an initial double-blind phase where neither participants nor researchers know the assigned treatment, followed by an open-label extension where all participants may receive the active drug. This design helps assess the drugs impact on heart failure and related cardiovascular events. During the study, participants will undergo regular assessments including questionnaires to measure heart failure symptoms and quality of life, blood tests for kidney function, blood sugar, cholesterol, and inflammation markers, as well as monitoring of heart failure events and mortality. The main outcome is the time until cardiovascular death or heart failure events over about 35 months. Safety and other health measures will also be tracked throughout the trial, which lasts up to about three years.

Age: 18Years - 99YearsAll GendersPhase 3
686 locations
I

Actively Recruiting

Researchers are studying how diets supplemented with polyunsaturated fatty acids PUFAs from animal or plant sources affect chronic inflammation linked to cardiovascular risk. The study focuses on people over 55 with moderate to high cardiovascular risk but without established cardiovascular disease. It aims to better understand how these dietary changes influence a lipid and inflammation-related risk score and improve overall cardiovascular prevention by addressing chronic inflammation. Participants are randomly assigned to one of three diets fish oil supplementation providing omega-3 fatty acids DHA and EPA, camelina oil supplementation rich in alpha-linolenic acid ALA plus vitamin E, or a regular non-enriched diet with vitamin E. The study product is taken daily for 12 weeks, with doses standardized to ensure comparable vitamin E intake. The supplementation is administered before meals, and all products are provided by the study team. During the study, participants undergo a baseline clinical visit with blood sampling, heart rate, blood pressure, and waist circumference measurements, and complete a dietary questionnaire. After 12 weeks, these assessments are repeated along with monitoring diet tolerance and any clinical events. Blood samples are stored and analyzed centrally to evaluate changes in lipid and inflammatory biomarkers. The study plans to enroll 324 participants, with outcomes measured primarily by changes in a lipidomicinflammation-based risk score over 12 weeks.

Age: 55Years +All GendersPhase Not Applicable
9 locations
E

Actively Recruiting

Researchers are conducting a Phase III international study to evaluate the effects of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in patients with chronic heart failure HF and impaired kidney function who have recently experienced a heart failure event. The study aims to assess the impact of these treatments on cardiovascular death and heart failure events, including hospitalizations and other HF-related episodes. Participants are randomly assigned to one of three groups one receiving balcinrenonedapagliflozin 15 mg10 mg capsule plus placebo another receiving balcinrenonedapagliflozin 40 mg10 mg capsule plus placebo and a third group receiving dapagliflozin 10 mg tablet plus placebo capsule. All treatments are given once daily orally, alongside standard care for heart failure and kidney impairment. The study is conducted across approximately 700 sites in about 40 countries. During the trial, participants will be monitored over approximately 36 months for cardiovascular death, heart failure hospitalizations, and heart failure events without hospitalization. Assessments include heart failure symptom scores measured at 24 weeks post-randomization. Researchers will also track total occurrences of cardiovascular and heart failure events, as well as overall mortality. This long-term follow-up aims to evaluate treatment effects on these important health outcomes.

Age: 18Years - 130YearsAll GendersPhase 3
852 locations